Sarepta Therapeutics, formerly AVI BioPharma, specializes in the development of leading-edge RNA-based therapeutics that improve and save the lives of those affected by serious and life-threatening rare and infectious diseases. The company’s varied pipeline includes eteplirsen, its lead program, for Duchenne muscular dystrophy; it also includes treatments for some of the most lethal infectious diseases in the world. For more information, visit the company’s Web site at www.sareptatherapeutics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: